a genome-wide association study (GWAS) identified SNPs in the chromosome 4q25 region that are associated with increased AF risk 7 .
We hypothesized that additional common genetic variation contributes to the development of AF. We conducted and combined metaanalyses of prevalent AF and incident AF, using existing GWAS data from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) AF Consortium. CHARGE included the following five community-based cohorts 8 : Age, Gene/Environment Susceptibility Reykjavik Study (AGES); Atherosclerosis Risk in Communities (ARIC); Cardiovascular Health Study; Framingham Heart Study; and Rotterdam Study. Genotyping inclusion criteria were unbiased toward AF, as genotyping was performed as a core effort for many phenotypes in each cohort. Study design and genotyping features are in Supplementary Tables 1 and 2 . Genotypes for more than 2.5 million SNPs were imputed within each study using reference genotype data and linkage disequilibrium patterns from the HapMap CEU population (Supplementary Methods).
Our community-based participants were middle-aged to elderly, with mean ages at DNA collection from 57 (ARIC) to 76 (AGES) years (Supplementary Table 3 ). To assess potential population stratification, we computed genomic inflation factors (l) of meta-analysis results: l was 1.005 for prevalent AF, 1.014 for incident AF and 1.026 for combined prevalent-incident AF (Supplementary Table 2 provides l by cohort and analysis). The observed versus expected P value distributions (quantile-quantile plots) and Manhattan plots of -log 10 P values for separate prevalent and incident AF analyses are displayed in Supplementary Figures 1 and 2 .
We prespecified genome-wide significance as P o 5 Â 10 À8 , corresponding to significance at 5% adjusting for approximately one million independent tests as estimated in HapMap samples of European ancestry. To prioritize follow-up genotyping, we required that SNPs have P o 4 Â 10 À7 (corresponding to one expected false positive per GWAS) and that at least six of nine analyses (out of four prevalent and five incident AF analyses) contribute results for the SNP, to reduce possible false-positives due to poor imputation.
The quantile-quantile plot and Manhattan plot of the meta-analysis of combined prevalent and incident AF are depicted in Supplementary Figure 3 . We replicated the association with a previously reported chromosome 4 locus 7 (rs17042171, P ¼ 6.0 Â 10 À27 ; Table 1 and Supplementary Fig. 4 ), which was approximately 150 kb telomeric to the transcription factor gene PITX2.
SNP rs2106261 on chromosome 16q22, located in an intronic region of transcription factor ZFHX3 (previously known as ATBF1), showed suggestive evidence of association ( Table 1 , combined prevalent-incident P ¼ 2.3 Â 10 À7 , Fig. 1 ). Results were consistent in the separate prevalent (P ¼ 9.0 Â 10 À6 ) and incident (P ¼ 7.9 Â 10 À4 ) AF analyses (Supplementary Table 4 provides cohort-specific estimates). We replicated the association between SNP rs2106261 and AF in a large independent cohort, the German AF Network (AFNET), consisting of 2,145 cases and 4,073 controls (odds ratio ¼ 1.44, P ¼ 1.6 Â 10 À11 ; Table 1 ). In a meta-analysis of the results from the discovery (CHARGE community AF) and replication (German AFNET) studies, rs2106261 was significantly associated with AF (RR 1.25, P ¼ 1.8 Â 10 À15 ; Table 1 ). ZFHX3 appears to regulate myogenic 9 and neuronal differentiation 10 . ZFHX3 has been reported to be a tumor suppressor gene in several cancers 11 , and recently SNPs in ZFHX3 have been associated with susceptibility to Kawasaki disease 12 . Although the function of ZFHX3 in cardiac tissue is unknown, it is expressed in mouse hearts 13 .
Another significant association signal was on chromosome 1p36 within MTHFR (rs17375901, P ¼ 4.6 Â 10 À8 ), which encodes 5,10-methylenetetrahydrofolate reductase. The association with the MTHFR locus was not confirmed in independent subjects from the AFNET cohort ( Table 1) . The initial MTHFR finding may be a false positive result. However, the region may merit further investigation because MTHFR is in linkage disequilibrium with NPPA, the atrial natriuretic peptide gene ( Supplementary Fig. 4) ; a NPPA frameshift mutation has been described in a family with AF 14 .
We acknowledge several study limitations. Although our findings were generally consistent, we observed some between-analysis heterogeneity in effect sizes (P ¼ 0.01), possibly arising from variation in cohort participant characteristics, duration and etiology of AF, low study-specific precision, subtle locus-specific population stratification and population differences in underlying haplotype structure. Population stratification at a larger scale did not seem to have a substantial impact on our findings as we did not observe inflation of the genomic control factors in the study-specific analyses or the meta-analyses. We note that for the previously validated PITX2 locus we observed between-study heterogeneity. Thus, heterogeneity appears to be a See Supplementary Table 3 for cohort-specific signals of top findings. For all odds, hazard and risk ratios, the reference group is the major allele homozygote; risk is expressed per each additional copy of the minor allele. B, regression estimate (log odds ratio for prevalent, log hazard ratio for incident). a Combination of odds and hazard ratios from four prevalent AF and five incident AF analyses. b P value for Cochran's statistic of heterogeneity of effect across the four prevalent and five incident analyses. c AFNET results for chromosome 4 were available for rs2200733, a perfect proxy for rs17042171 (r 2 ¼ 1) in HapMap CEU samples. In CHARGE, the previously reported chromosome 4 SNP, rs2200733, for combined prevalent and incident AF had risk ratio ¼ 1.44, P ¼ 9.3 Â 10 À27 ; for prevalent AF, odds ratio ¼ 1.59; P ¼ 3.3 Â 10 À11 ; for incident AF, hazard ratio ¼ 1.
general feature of even the strongest genome-wide findings for AF, and it remains to be addressed in follow-up studies. In addition, our findings may not be generalizable to other populations. It also was not possible to perform a pooled analysis using participant-specific data given the restrictions imposed by the Institutional Review Boards at some study sites. Furthermore, there is a potential for survival bias in the prevalent AF analysis if the variant is associated with both AF onset and lethality; in this situation, individuals who die shortly after AF onset might not survive until DNA collection. Nonetheless, a moderate association was present in prevalent, incident, and combined AF metaanalyses for both the validated chromosome 4q25 and the new chromosome 16q22 loci. Another limitation is that, beyond single SNPs, our study did not analyze patterns of haplotypes, and thus this it may not have captured complex haplotype associations. However, our use of imputation to the HapMap does take advantage of available linkage disequilibrium information. Finally, we recognize that we likely have identified variants in linkage disequilibrium with causal variants rather than the specific functional variants; the pathophysiology by which locus variation contributes to AF risk remains unknown. The strengths of our approach include the use of five large community-based cohorts, whose participants were not selected for phenotypic characteristics, thereby enhancing the generalizability of our findings. The robustness of the chromosome 16q22 result is strengthened by its documentation in samples ascertained with different study designs, including case-control and cohort studies.
In summary, by examining GWAS data for AF in five communitybased cohorts, we replicated the previously reported association with chromosome 4q25 variants and we identified a new locus on chromosome 16 in a gene encoding the transcription factor ZFHX3. We provided confirmatory support for the ZFHX3 finding by replicating our findings in a large independent study of AF. Further studies are needed to elucidate functional variants and mechanisms by which the 16q22 locus predisposes to AF. 
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